No Image

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program

DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) (“SpringWorks”) today announced that Jazz Pharmaceuticals Ireland Limited (“Jazz”) and SpringWorks have entered into an asset purchase and exclusive license agreement under which Jazz has acquired SpringWorks’ fatty acid amide hydrolase (“FAAH”) inhibitor program including PF-04457845. Jazz will initially focus on developing PF-04457845 for the potential treatment of post-traumatic stress disorder (“PTSD”) and associated symptoms.

Read More

No Image

Severn Bancorp, Inc. Announces Third Quarter Earnings

ANNAPOLIS, Md., Oct. 22, 2020 /PRNewswire/ — Severn Bancorp, Inc. (the Company) (NASDAQ: SVBI), the parent company of Severn Bank (the Bank), reported net income of $1.9 million for the third quarter ended September 30, 2020 and $4.2 million for the nine months ended September 30, 2020 compared to $2.4 million and $7.2 million for the same periods in 2019. Earnings per share on a fully diluted basis were $0.15 for the third quarter and $0.33 per share for the first nine months of 2020, down from $0.19 and $0.56 per share, respectively, from the third quarter and first nine months of 2019.